Abstract
Background Blood transfusions may adversely affect the prognosis of patients treated surgically for cancer, although definite proof of this adverse effect has not been reported. Methods We carried out a randomized trial to investigate whether the prognosis in patients with colorectal cancer would be improved by a program of autologous blood transfusion as compared with the current practice of allogeneic transfusion. Patients in the autologous-transfusion group were required to donate two units of blood before surgery. Results A total of 475 patients were evaluated. We found no significant difference in prognosis between the allogeneic-transfusion group (236 patients) and the autologous-transfusion group (239 patients); colorectal cancer-specific survival rates at four years were 67 percent and 62 percent, respectively (P = 0.39). Among the 423 patients who underwent curative surgery, 66 percent of those in the allogeneic-transfusion group and 63 percent of those in the autologous-transfusion group had no ...
Cite
CITATION STYLE
Harlaar, J. J., Gosselink, M. P., Hop, W. C. J., Lange, J. F., Busch, O. R. C., & Jeekel, H. (2012). Blood Transfusions and Prognosis in Colorectal Cancer. Annals of Surgery, 256(5), 681–687. https://doi.org/10.1097/sla.0b013e318271cedf
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.